文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 2014--N Engl J Med--Multitarget Stool DNA Testing for Colorectal-Cancer Screening
侵权投诉

2014--N Engl J Med--Multitarget Stool DNA Testing for Colorectal-Cancer Screening

结肠癌新型DNA筛查工具

The new england journal of medicine

Multitarget Stool DNA Testing for Colorectal-Cancer Screening

Thomas F. Imperiale, M.D., David F. Ransohoff, M.D., Steven H. Itzkowitz, M.D.,

Theodore R. Levin, M.D., Philip Lavin, Ph.D., Graham P. Lidgard, Ph.D.,

David A. Ahlquist, M.D., and Barry M. Berger, M.D.

ABSTRACT

Background

An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening.

Methods

We compared a noninvasive, multitarget stool DNA test with a fecal immunochem-ical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 meth-ylation, and β-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings.

Results

Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the greatest dimension) on colonoscopy. The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P = 0.002). The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT (P = 0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT were 86.6% and 94.9%, respectively, among participants with nonadvanced or neg-ative findings (P<0.001) and 89.8% and 96.4%, respectively, among those with negative results on colonoscopy (P<0.001). The numbers of persons who would need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA testing, and 208 with FIT.

Conclusions

From the Department of Medicine, Indi-ana University School of Medicine, the Regenstrief Institute, the Simon Cancer Center, and the Center for Innovation at Roudebush Veterans Affairs Medical Center — all in Indianapolis (T.F.I.); the Departments of Medicine and Epidemi-ology and the Lineberger Comprehensive Cancer Center, University of North Caro-lina at Chapel Hill, Chapel Hill (D.F.R.); the Dr. Henry D. Janowitz Division of Gastro-enterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York (S.H.I.); Kaiser Permanente Medical Center, Walnut Creek, CA (T.R.L.); Boston Biostatistics Research Founda-tion, Framingham MA (P.L.); Exact Sci-ences, Madison, WI (G.P.L., B.M.B.); and the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN (D.A.A.). Address reprint requests to Dr. Imperiale at Indiana University Medical Center–Regenstrief Institute, 1050 Wis-hard Blvd., Indianapolis, IN 46202.This article was published on March 19, 2014, at NEJM.org.

DOI: 10.1056/NEJMoa1311194

Copyright © 2014 Massachusetts Medical Society.

In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.)

n engl j med nejm.org

1

2014--N Engl J Med--Multitarget Stool DNA Testing for Colorectal-Cancer Screening

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email